Median progression-free survival (PFS) from first randomization was 20.2 months after CHOP versus 33.1 months after R-CHOP (hazard ratio, 0.65 P <. R-CHOP induction yielded an increased overall response rate (CHOP, 72.3% R-CHOP, 85.1% P <. Those in complete remission (CR) or partial remission (PR) were randomized to maintenance with R (375 mg/m 2 intravenously once every 3 months for a maximum of 2 years) or observation. A total of 465 patients were randomized to induction with 6 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) (every 3 weeks) or R-CHOP (R: 375 mg/m 2 intravenously, day 1). Bugs and glitches however, are accepted.We evaluated the role of rituximab (R) both in remission induction and maintenance treatment of relapsed/resistant follicular lymphoma (FL). Any threads/posts that link to or provide examples of hacks, macros, piracy, or "apks" will be deleted and the posters will be banned.Cursing is permitted, as long as it is not directly offensive.
There will be no tolerance for comments or posts that attacks the person. Links to YouTube videos with no accompanying text or are seen as "useless" or self-promotion will be removed.This includes "unmeaningful" or low-effort content. Posts that are seen as "repetitive" or spam-related will be removed.
0 kommentar(er)
